Opportunity Information: Apply for PA 16 072
Apply for PA 16 072
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Behavioral and Integrative Treatment Development Program (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279,.
- This funding opportunity was created on Jan 08, 2016 and posted on Jan 08, 2016.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Behavioral and Integrative Treatment Development Program (R01) is a National Institutes of Health (NIH) funding opportunity (PA-16-072, HHS-NIH11) that supports research focused on developing and rigorously testing behavioral and combined behavioral-pharmacological interventions for drug abuse treatment and related health challenges. The overarching goal is to move beyond early feasibility work and fund well-designed studies that can demonstrate whether an intervention works, how it works, and how to deploy it more effectively in real-world settings. The announcement emphasizes intervention development and refinement through efficacy testing and clinical trials, including research that identifies mechanisms of behavior change, evaluates dose-response relationships (how much intervention is needed to achieve an effect), improves or optimizes multi-component approaches, and determines the best sequencing of intervention elements (for example, when behavioral strategies should be delivered before, alongside, or after medication-based treatment).
A central theme of the opportunity is improving drug abuse treatment outcomes across diverse populations and service environments, including people with co-occurring conditions and complex clinical needs. The FOA encourages projects that test behavioral treatments alone as well as integrated models that combine behavioral approaches with pharmacological treatments. This includes research on combined, sequential, or fully integrated care pathways, where investigators can examine which combinations produce better outcomes, whether certain patients benefit more from specific sequences, and what components drive change. The intent is to support studies that yield actionable evidence about what works, for whom, and under what conditions, rather than only demonstrating that an intervention can be delivered.
Several specific research areas are highlighted. First, the FOA encourages drug abuse treatment interventions (including adherence-focused approaches) that can be used in a range of settings, reflecting the reality that treatment occurs in specialty programs, community clinics, justice-involved contexts, and other service systems. Second, it specifically calls for treatment and adherence interventions suitable for primary care, recognizing the expanding role of primary care teams in screening, brief intervention, medication management, and ongoing support for substance use disorders. Third, the FOA prioritizes interventions that leverage technology to strengthen outcomes and make implementation more practical. This can include digital tools and platforms designed to boost engagement, deliver intervention content more consistently, extend support outside clinic visits, reduce burden on providers, and improve scalability.
The FOA also highlights the intersection of substance use treatment and HIV prevention. It encourages interventions aimed at preventing acquisition or transmission of HIV among individuals in drug abuse treatment, acknowledging elevated risk in some populations and the importance of integrating prevention strategies within treatment systems. Relatedly, it supports interventions designed to improve adherence not only to drug abuse treatment itself, but also to HIV medications and addiction medications, since adherence is a key determinant of outcomes across these conditions. Another area of interest is interventions to treat chronic pain, which is closely linked to substance use risk and can complicate treatment planning; the FOA supports behavioral and integrative approaches that address pain in ways that may reduce reliance on high-risk medication use and improve functioning.
In terms of the stage of science, the announcement explicitly points to Stage II and Stage III efficacy research as within scope. Practically, this signals interest in studies that are past initial concept development and pilot feasibility and are ready for more rigorous testing, including controlled trials, stronger designs to establish efficacy, and careful measurement of mediators and moderators (mechanisms and for-whom effects). Applicants are expected to focus on producing credible evidence about intervention impact and to generate insights that help optimize the intervention for broader use.
This is an R01 grant mechanism, meaning it is intended for substantial, hypothesis-driven research projects with a clear plan for intervention testing and evaluation. Eligible applicants are broad and include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (excluding small businesses and also including small businesses as a separate eligible category); and other entities as allowed in the FOA’s eligibility details. The funding activity category is listed under Education and Health, and the program aligns with CFDA numbers 93.273 and 93.279. The opportunity was posted January 8, 2016, with an original and current closing date of January 7, 2019; award ceiling and expected award counts were not specified in the provided listing.
Frequently Asked Questions (FAQs)
What is the Behavioral and Integrative Treatment Development Program (R01)?
The Behavioral and Integrative Treatment Development Program (R01) is a National Institutes of Health (NIH) funding opportunity (PA-16-072, HHS-NIH11) that supports research to develop, refine, and rigorously test behavioral and combined behavioral-pharmacological interventions for drug abuse treatment and related health challenges.
What is the main goal of this funding opportunity?
The main goal is to move beyond early feasibility or pilot work and support well-designed studies that can show whether an intervention works, how it works (mechanisms of behavior change), and how to deploy it more effectively in real-world service settings.
What types of interventions are in scope?
The opportunity supports behavioral interventions as well as integrated approaches that combine behavioral strategies with pharmacological treatments. This includes combined, sequential, or fully integrated care pathways.
Does the program support clinical trials and efficacy testing?
Yes. The announcement emphasizes intervention development and refinement through efficacy testing and clinical trials, including rigorous designs intended to establish intervention impact.
What stages of research are specifically encouraged?
The FOA explicitly points to Stage II and Stage III efficacy research as within scope, meaning projects should generally be past initial concept development and early feasibility and be ready for more rigorous testing.
Is early feasibility or pilot work the focus of this program?
No. The program is positioned as moving beyond early feasibility work and instead funding studies designed to generate credible evidence about effectiveness and how to optimize the intervention for broader use.
What does the FOA mean by understanding "how it works"?
It refers to research that identifies mechanisms of behavior change and includes careful measurement of mediators and moderators to understand what drives outcomes and for whom the intervention works best.
What is meant by "for whom, and under what conditions"?
This refers to generating actionable evidence about which populations benefit, which settings are most suitable, and what contextual factors influence outcomes, rather than only showing that an intervention can be delivered.
Are dose-response questions relevant to this FOA?
Yes. The announcement highlights evaluating dose-response relationships, such as how much intervention is needed to achieve an effect.
Does the FOA support optimizing multi-component interventions?
Yes. It encourages research that improves or optimizes multi-component approaches and determines which components are most important in producing change.
Can applicants study the sequencing of intervention components?
Yes. The FOA emphasizes determining the best sequencing of intervention elements, such as whether behavioral strategies should be delivered before, alongside, or after medication-based treatment.
Are projects focused on diverse populations and complex clinical needs encouraged?
Yes. A central theme is improving treatment outcomes across diverse populations and service environments, including people with co-occurring conditions and complex clinical needs.
What service settings are considered relevant for intervention testing?
The FOA highlights the reality that drug abuse treatment occurs across multiple settings, including specialty programs, community clinics, justice-involved contexts, and other service systems.
Does this opportunity include interventions suitable for primary care?
Yes. It specifically calls for treatment and adherence interventions suitable for primary care, reflecting the expanding role of primary care teams in screening, brief intervention, medication management, and ongoing support for substance use disorders.
Are technology-based or digital interventions encouraged?
Yes. The FOA prioritizes interventions that leverage technology to strengthen outcomes and make implementation more practical, including tools to boost engagement, deliver content consistently, extend support outside visits, reduce provider burden, and improve scalability.
Does the FOA support research on treatment adherence?
Yes. It highlights drug abuse treatment interventions including adherence-focused approaches, and also supports interventions aimed at improving adherence to HIV medications and addiction medications.
Is HIV prevention part of the scope of this opportunity?
Yes. The FOA highlights the intersection of substance use treatment and HIV prevention and encourages interventions aimed at preventing acquisition or transmission of HIV among individuals in drug abuse treatment.
Can projects address adherence to HIV medications as well as addiction medications?
Yes. The FOA supports interventions designed to improve adherence to HIV medications and addiction medications, recognizing adherence as a key determinant of outcomes.
Does this FOA include interventions addressing chronic pain?
Yes. It supports behavioral and integrative approaches to treat chronic pain, recognizing its close link to substance use risk and the way it can complicate treatment planning.
What is meant by "integrative" in this program context?
Based on the description provided, "integrative" includes combined behavioral-pharmacological interventions and integrated models where behavioral approaches are paired with medication-based treatment in combined, sequential, or fully integrated pathways.
What grant mechanism is used for this opportunity?
This opportunity uses the R01 grant mechanism, intended for substantial, hypothesis-driven research projects with a clear plan for intervention testing and evaluation.
Who is eligible to apply?
Eligible applicants are broad and include state, county, and local governments; public and private institutions of higher education; independent school districts; special district governments; federally recognized tribal governments and other tribal organizations; public housing and Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (with small businesses also referenced as an eligible category); and other entities as allowed in the FOA eligibility details.
What agency is offering this funding opportunity?
The funding opportunity is offered through the National Institutes of Health (NIH).
What are the opportunity identifiers?
The opportunity is identified as PA-16-072 and HHS-NIH11.
What is the funding activity category listed for this opportunity?
The funding activity category is listed under Education and Health.
Which CFDA numbers are associated with this program?
The program aligns with CFDA numbers 93.273 and 93.279.
When was the opportunity posted?
The opportunity was posted on January 8, 2016.
What is the closing date for this opportunity?
The original and current closing date listed is January 7, 2019.
Is an award ceiling provided?
No. The award ceiling was not specified in the provided listing.
Is the expected number of awards provided?
No. The expected award count was not specified in the provided listing.
What kinds of outcomes is the FOA trying to produce?
The FOA aims to support studies that yield actionable evidence about what works, how and why it works, for whom it works best, and how to deploy interventions more effectively in real-world settings.
Browse more opportunities from the same category: Education, Health
Next opportunity: ROSES 2015: Carbon Monitoring System
Previous opportunity: Alaska Native-Serving and Native Hawaiian-Serving Institutions Education Competitive Grants Program (ANNH)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 072
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 072) also looked into and applied for these:
| Funding Opportunity |
|---|
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Emerging Questions in Cancer Systems Biology (U01) Apply for PAR 16 131 Funding Number: PAR 16 131 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25) Apply for PAR 16 138 Funding Number: PAR 16 138 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| The Early Detection Research Network: Biomarker Developmental Laboratories (U01) Apply for RFA CA 16 009 Funding Number: RFA CA 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Coordinating Center for Barrett's Esophagus Translational Research Network (BETRNet)(U24) Apply for RFA CA 16 007 Funding Number: RFA CA 16 007 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) Apply for PAR 16 139 Funding Number: PAR 16 139 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Research Centers for Barretts Esophagus Translational Research Network (BETRNet)(U54) Apply for RFA CA 16 006 Funding Number: RFA CA 16 006 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $900,000 |
| Population Health Interventions: Integrating Individual and Group Level Evidence (R21) Apply for PA 16 147 Funding Number: PA 16 147 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Role of Astrocytes and Astrocytic Networks in Drug Abuse (R21) Apply for PA 16 145 Funding Number: PA 16 145 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 072", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.